Compare ESP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | MDWD |
|---|---|---|
| Founded | 1928 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 162.2M |
| IPO Year | 1995 | 2013 |
| Metric | ESP | MDWD |
|---|---|---|
| Price | $52.03 | $12.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.67 |
| AVG Volume (30 Days) | 31.4K | ★ 79.3K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 28.81 | N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $46,124,325.00 | N/A |
| Revenue This Year | $13.61 | $39.60 |
| Revenue Next Year | $5.53 | $34.34 |
| P/E Ratio | $13.20 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.82 | $11.84 |
| 52 Week High | $74.77 | $19.70 |
| Indicator | ESP | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 25.55 | 39.47 |
| Support Level | $48.80 | $11.84 |
| Resistance Level | $56.77 | $14.06 |
| Average True Range (ATR) | 1.89 | 0.50 |
| MACD | -0.81 | -0.04 |
| Stochastic Oscillator | 10.46 | 11.54 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.